Indication
Epstein-Barr Virus-Related Lymphoproliferative Disorder
1 clinical trial
5 products
Clinical trial
Constitutive IL7 (C7R) Modified EBV Specific T-Lymphocytes for Treatment of EBV-Positive LymphomaStatus: Recruiting, Estimated PCD: 2024-03-30
Product
Dose Level 1AProduct
Dose Level 2AProduct
Dose Level 2BProduct
Dose Level 3BProduct
Dose Level 3A